Business
Nutriband Inc. Files Pro Forma Financials Consolidating the Recent Acquisition of Pocono Coated Products Transdermal and Topical Business and Active Intelligence
ORLANDO, Fla., Jan. 13, 2021 /PRNewswire/ -- Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, filed its form 8-K/A with the SEC for the audited financial
About this update from Nutriband Inc.
[{"type":"text","content":"ORLANDO, Fla., Jan. 13, 2021 /PRNewswire/ -- Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, filed its form 8-K/A with the SEC for the audited financial reports of both Pocono Coated Products LLC and Active Intelligence and the combined pro forma financial statements with Nutriband Inc. \n\nAbout Nutriband Inc.\nThe Company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is its abuse deterrent fentanyl transdermal system which the Company is developing to provide clinicians and patients with an abuse deterrent transdermal fentanyl product for use in managing chronic pain requiring opioid therapy. The product is combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches.\nThe Company's website is www.nutriband.com 4P's (Subsidiary) website is www.4PTherapeutics.com. Pocono Pharma's (Subsidiary) website is www.poconopharma.com Any material contained in or derived from any of the company's websites or any other website is not part of this press release.\nAbout Our Forward-Looking Statements\nCertain statements contained in this press release, including, without limitation, statements containing the words \"believes,\" \"anticipates,\" \"expects,\" plans and words of similar import, constitute \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast it...